Interim Order
187 interim order decisions from Delhi High Court - Orders.
Interim Order Decisions
187 cases | Page 6 of 7
Chugai Seiyaku Kabushiki Kaisha & Anr v.Natco Pharma Limited
Chugai Seiyaku Kabushiki Kaisha filed a suit seeking an ad interim injunction against Natco Pharma Limited, alleging infringement of Indian Patent No. IN 294424 concerning Alectinib. The court allowed the application subject to exceptions and noted that while the defendant could use the drug for research under Section 107A, any commercial launch would require prior permission from the court.
Wheelseye Technology India Pvt. Ltd. v.Zinka Logistics Solutions Pvt. Ltd. & Ors.
Wheelseye Technology filed a suit alleging that its competitor, Zinka Logistics Solutions, along with several former WheelsEye employees, conspired to disrupt the business. The Defendants allegedly misappropriated Confidential Information, solicited employees through en masse poaching, and induced breaches of contractual obligations.
Anay Kumar Gupta v.Jagmeet Singh Bhatia
The Delhi High Court allowed an interim application filed by Anay Kumar Gupta against Jagmeet Singh Bhatia in a suit concerning trademark infringement. The court granted an immediate injunction restraining the defendant from continuing to manufacture and sell whisky using the 'EVERSHINE PREMIUM CLASSIC WHISKY' label, bottle shape, or logo AWB. This order was issued after the plaintiff demonstrated that the agreements allowing the use of the mark had expired, leading to alleged unauthorized continued use by the defendant.
Chugai Seiyaki Kabushiki Kaisha v.MSN Laboratories Private Limited
The plaintiffs filed a suit seeking an ad interim injunction against MSN Laboratories Private Limited for infringing Indian Patent No. IN 294424, which covers Alectinib or its derivatives. The court allowed the application subject to exceptions, permitting the defendant to use the drug for research purposes under Section 107A of the Patents Act, but prohibiting commercial launch without prior court permission.
Sun Pharmaceuticals Industries Ltd v.Union Of India & Ors.
Sun Pharmaceuticals Industries Ltd filed a writ petition seeking directions for the expeditious disposal of opposition proceedings against Patent No. 257402, which was granted to Novo Nordisk A/S. The court addressed the procedural delay and directed the respondents to furnish the Opposition Board's recommendations within one week, subsequently rescheduling the hearing.
Nokia Technologies Oy v.Guangdong Oppo Mobile Telecommunications Corp., Ltd.
The petitioner (Nokia Technologies Oy) filed an application seeking temporary injunction and disclosure of assets against the respondent (Guangdong Oppo Mobile). The court, while addressing various interlocutory applications, granted a direction for the defendants to furnish specific disclosures regarding their sales and revenues related to the alleged infringing devices.
Abhishek Kumar v.Union Of India Through Registrar Of Copyrights & Ors.
Abhishek Kumar filed a petition under Section 50 of the Copyright Act seeking to expunge the copyright registration of the 'Turbo Plus' label, which was registered as an artistic work. The petitioner also sought the suspension of this registration's effect to protect against potential infringement threats. Given the ongoing proceedings before the Trademark Registry regarding the cancellation of a search certificate, the court renotified the matter for further hearing.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging the procedural approach of the Patent Controller, arguing that its application for cross-examination of expert witnesses had not been decided. The court observed the long pendency and directed the Controller to first dispose of Natco's cross-examination application before proceeding with the merits of Novartis' patent application.
M/S Reflect Sculpt Private Ltd. v.Musky Couture
The Delhi High Court allowed M/S Reflect Sculpt Private Ltd. to proceed with its suit against Musky Couture, which alleges infringement of the 'GAURAV GUPTA' trademark and copyright in unique artistic garments. The Plaintiff detailed how the Defendant was allegedly manufacturing and selling identical, low-budget imitations while falsely claiming association with the original designer. Crucially, the Court issued a significant interim order allowing a Local Commissioner to conduct a search and seizure of the Defendant's premises in Mumbai to gather evidence of infringement.
Merck Sharp And Dohme Corp v.Indilina Pharmaceuticals
Merck Sharp & Dohme Corp (Plaintiff) filed a suit seeking an injunction against Indilina Pharmaceuticals (Defendant) for infringing their patent (IN'816) covering the compound Sitagliptin. The Plaintiffs alleged that the Defendant was offering tablets of Sitagliptin for sale in tenders. The Court granted interim relief restraining the Defendant from any infringing activities and directed disclosure of profits.
H. Lundbeck A/S v.Hetero Drugs Limited
The dispute involves H. Lundbeck A/S challenging Hetero Drugs Limited's export activities, which are claimed by the defendants to be permissible under Section 107A of the Patents Act for R&D purposes. The court issued an interim order allowing the defendants to continue exports to seven specified entities while addressing objections raised by the plaintiff.
H. Lundbeck A/S v.Hetero Drugs Limited
H. Lundbeck A/S filed a suit against Hetero Drugs Limited regarding alleged infringement of Patent IN227963, which covers Vortioxetine Hydrobromide. During the hearing, the defendants asserted that they were not commercially launching any product and were using the substance solely for regulatory and R&D purposes.
Merck Sharp And Dohme Corp & Anr v.Actis Generics Pvt Ltd
The Plaintiffs, Merck Sharp & Dohme Corp. and Sun Pharmaceutical Industries Ltd., filed a suit seeking an injunction against Actis Generics Pvt Ltd for infringing Patent No. IN'816, which covers the compound Sitagliptin. The court examined the prima facie case and found that the Defendant was distributing and selling infringing Sitagliptin API without authorization.
Merck Sharp And Dohme Corp v.Chiral Biosciences Limited
The plaintiffs, Merck Sharp And Dohme Corp, filed a suit alleging infringement of their Indian Patent No. 209816 covering Sitagliptin, a DPP-4 inhibitor used to treat Diabetes Mellitus Type II. The court issued an order granting an ex parte ad interim injunction restraining the defendant from manufacturing or dealing in infringing products until further hearing.
Pharmacyclics Llc. v.Alkem Laboratories Ltd.
The Delhi High Court addressed a commercial suit filed by Pharmacyclics Llc. against Alkem Laboratories Ltd., alleging infringement of Patent IN 262968. The court noted that the plaintiffs had other related suits pending before different benches regarding the same patent. Consequently, the court ordered the listing of the current suit for further consideration.
H Lundbeck A/S v.Hetero Drug Ltd.
The plaintiffs alleged that the defendants were infringing their patent (IN 227963) by manufacturing and exporting substantial quantities of the anti-depressant drug Vortioxetine. The court found a prima facie case in favour of the plaintiffs, considering the allegations of export and potential use under Section 107 of the Patents Act.
ASTRAZENCA AB & ANR v.AJANTA PHARMA LTD.
The plaintiffs filed a suit alleging infringement of their patent IN '625. The present order addressed the defendant's request for an early hearing, noting that in connected suits, the court had previously declined interim injunctions.
ASTRAZENECA AB & ANR. v.MICRO LABS LIMITED
The plaintiff, AstraZeneca, filed a suit alleging infringement of its genus (IN 147) and species (IN 625) patents for the drug DAPAGLIFLOZIN (brand name FORXIGA). The defendant, Micro Labs Limited, was accused of manufacturing, selling, and seeking approval for generic versions. The court granted an ex-parte ad-interim injunction in favour of the plaintiff.
Merck Sharp and Dohme Corp & Anr. v.Cleanchem Laboratories Llp
The plaintiffs, owners of Indian Suit Patent IN 209816 for SITAGLIPTIN, filed a suit alleging that the defendant was selling and dealing in SITAGLIPTIN without a license. The court found prima facie evidence of violation and granted an ad-interim ex-parte injunction.
BASF SE v.UPL LIMITED
The plaintiff, BASF SE, filed a suit claiming infringement of its patent (IN-262428) covering the superior anhydrous-II form of the fungicide BOSCALID. The defendant, UPL Limited, appeared and submitted that no valid patent existed for the specific anhydrous-II form at the time they applied for licenses, asserting their use was limited to R&D.
Astrazeneca Ab v.Union Of India
Astrazeneca challenged an order from the Patent Office that directed immediate publication of its granted patent (IN 235625) due to a clerical error. The petitioner argued that this belated direction, after 11 years, would prejudice them by effectively extending the statutory limitation period for post-grant opposition beyond one year as stipulated in Section 25(2).
UPL Limited v.Modern Insecticides Limited
UPL Limited filed a suit alleging that Modern Insecticides Limited was infringing its statutory rights by exporting and intending to manufacture a product covered by patent IN 244551. The composition in question is a synergistic herbicide comprising Metsulfuron Methyl and Sulfosulfuron.
Astrazenca Ab v.Ajanta Pharma Ltd.
The court heard an application seeking condonation of a 6-day delay by the defendant, which was granted. The court also directed the parties regarding the filing of written statements and clarified the validity dates of the two patents (IN '147 and IN '625) held by Astrazenca Ab.
Astrazenca Ab & Anr v.West Coast Pharmaceuticals Works Ltd.
The Delhi High Court heard the matter concerning suit patents held by Astrazenca Ab & Anr against West Coast Pharmaceuticals Works Ltd. The court addressed the validity dates of the two patents (IN '147 and IN '625) and accepted an undertaking from the defendant that they do not manufacture or sell infringing products related to Dapagliflozin.
Merck Sharp And Dohme Corp. v.Honour Lab Limited
Merck Sharp And Dohme Corp. filed a suit alleging that Honour Lab Limited was infringing their Indian Patent No. 209816, which covers the molecule SITAGLIPTIN (an API for diabetes treatment). The plaintiffs sought interim relief against the defendant's alleged commercial supply of the patented API.
Sterlite Technologies Limited v.Ztt India Private Limited
The plaintiff sought the discovery of two sets of documents from the defendant: those concerning the manufacturing process of optical fibre and sales data. The court allowed the discovery of sales documents, requiring the defendant to file its audited balance sheet. However, the court denied the immediate necessity of discovering the manufacturing process documents, stating that the initial burden of proof remains with the plaintiff.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Bdr Pharmaceuticals International Pvt. Ltd & Anr.
The plaintiffs filed an application seeking action under Contempt of Court because defendant No.1 submitted a tender offering for the sale of Apixaban, despite a prior interim injunction restraining them from dealing in any infringing product covered by Indian Patent No. IN 247381. The court issued show cause notices to the Chairman and Director of defendant No.1 regarding potential contempt proceedings.
Merck Sharp & Dohme Corp. v.Angels Pharma India Private Limited
Merck Sharp & Dohme Corp. filed a suit alleging that Angels Pharma India Private Limited was attempting to manufacture and infringe its Indian Patent No. 209816, which covers the drug SITAGLIPTIN. The court found that the plaintiffs had established a prima facie case and granted interim relief.
Merck Sharp & Dohme Corp And Anr v.Oceanic Pharmachem Pvt. Ltd.
The plaintiffs filed a suit alleging that the defendant was infringing their Indian Patent No. 209816, which covers Sitagliptin and its salts. The plaintiff submitted evidence showing the defendant's online presence advertising and selling infringing Sitagliptin Phosphate API in India. Based on this prima-facie case, the court granted an ad-interim injunction restraining the defendant from dealing in the infringing product.
Merck Sharp & Dohme Corp. v.Everest Organics Limited
Merck Sharp & Dohme Corp. filed a suit seeking permanent injunction against Everest Organics Limited for infringing its registered patent No. 209816, which covers the molecule SITAGLIPTIN. The Plaintiffs alleged that the Defendant was developing and preparing to commercialize an infringing product. Based on the prima facie case presented, the Court granted an ad-interim ex-parte injunction.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.